Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBIT Margin: 2020-2025

Historic EBIT Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -226.92%.

  • Foghorn Therapeutics' EBIT Margin rose 7856.00% to -226.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -352.87%, marking a year-over-year increase of 5527.00%. This contributed to the annual value of -454.31% for FY2024, which is 13838.00% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' EBIT Margin stood at -226.92%, which was up 18.72% from -279.17% recorded in Q2 2025.
  • Foghorn Therapeutics' EBIT Margin's 5-year high stood at -97.73% during Q3 2023, with a 5-year trough of -64,051.22% in Q3 2021.
  • Moreover, its 3-year median value for EBIT Margin was -386.64% (2024), whereas its average is -429.18%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 5,372,217bps in 2021, then skyrocketed by 6,362,525bps in 2022.
  • Foghorn Therapeutics' EBIT Margin (Quarterly) stood at -3,938.57% in 2021, then soared by 317,648bps to -762.09% in 2022, then skyrocketed by 32,080bps to -441.29% in 2023, then plummeted by 39,922bps to -840.51% in 2024, then surged by 7,856bps to -226.92% in 2025.
  • Its EBIT Margin was -226.92% in Q3 2025, compared to -279.17% in Q2 2025 and -384.96% in Q1 2025.